Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerTargeted Therapies in Triple-Negative Breast CancerTriple negative breast cancer: looking for the missing link between biology and treatmentsThe role of taxanes in triple-negative breast cancer: literature reviewAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsIxabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trialStabilized Polymer Micelles for the Development of IT-147, an Epothilone D Drug-Loaded FormulationSystematic review of ixabepilone for treating metastatic breast cancer.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.nab-Paclitaxel dose and schedule in breast cancerThe treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.Update on taxane development: new analogs and new formulationsClinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.The management of early-stage and metastatic triple-negative breast cancer: a review.Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports.Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain.nab-Paclitaxel for the treatment of breast cancer: an update across treatment settingsChemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: a Korean Gynecologic Oncology Group study (KGOG-3021)Cancer nanomedicine: progress, challenges and opportunities.Clinical Development of Anti-mitotic Drugs in Cancer.An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials.Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer.Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.Nano-Photothermal ablation effect of Hydrophilic and Hydrophobic Functionalized Gold Nanorods on Staphylococcus aureus and Propionibacterium acnes.What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future
P2860
Q26745420-940C8D4F-67C9-42E5-80B3-D7A97E50374EQ26752846-990AF706-4A29-41F4-B672-B3239923EED8Q26777736-39B85E15-EA21-4A57-A186-7D46ACFC11F9Q26783122-30AB1279-2BBB-45FE-B0B5-6BA29DC33549Q26798356-8FF8D12D-D618-455A-980A-033687811E9EQ26798674-5AFDD571-011B-4D66-920B-7C10276B3A37Q28534786-381C1992-2442-4896-A9D3-868AF3087128Q28817437-91DC38B6-444A-4E8C-A655-6D1BD0693BFBQ30248627-552025EF-7588-4782-89DE-57454CF3901FQ33424566-8696AA5D-9028-4E89-8E41-FA3786882A06Q35734193-48421B4D-0410-48C0-8FA8-884B2A7E5783Q36416904-29ADB8CF-A164-4251-996A-F1E0479B6763Q36470377-6EAD4197-302C-43AD-8752-BCDA25188F6DQ36568558-D08344ED-2374-4D9D-8C02-0009E707D05EQ36678462-4A954B8E-9EE1-4FF2-8D12-A9A0C8B98EF9Q37080240-B9E3D2E0-3405-4C55-97E5-49F92D5CAE19Q37229422-A1E0DC98-CA9E-4114-9118-EC42FEE0DA00Q37398077-9613D729-73A7-4E74-983B-432026308786Q37715554-D68DE92F-4FB4-4653-B3B5-CD4C24CD2D76Q38245797-AA6B5445-F27D-4E71-8D11-B27FAF91B195Q38662419-CA5E68AE-3E2F-4414-91BE-06B5893B38A4Q38722948-8172176C-4458-4A76-A263-20939CA07F2FQ38839151-44EEAC3D-A844-462D-A12D-D422122109D7Q38889304-2891B4A1-CB7A-495A-AB86-15DC39B495C5Q39005226-8D542E67-1B20-40FD-90BB-CAC742B0F971Q39363642-16DF59BE-4031-4A61-A4F9-28A1195CABB2Q39400420-C93ADE62-7895-44A1-A0A1-D9CB622AB135Q41460534-2F18DD8C-B80B-4D6F-96EF-80B09F964C6AQ41899577-CA129DAE-3ADC-480D-AE0E-3400C1DB0E08Q42700716-A6D83851-ACF6-4C1F-9D69-451FD97F2BDAQ45932069-F9BBAA21-723C-4A4B-A78C-43380CCEA8F5Q46446983-8938DEDF-AE60-4EBE-8296-2923A91A7A94Q47142616-1A82DC97-3477-49FD-8E17-D309B70A1E40Q50074147-C51CA71C-7DAF-47B5-AB70-5B41236C846FQ50114923-0AF9D85C-769D-44B0-A29E-F110F8670FFAQ51154238-100BDF9E-04DC-4625-A5F9-EA73CE15FADEQ53384579-CB2C275A-8B15-417A-9E73-7E5F3EABD4EAQ55092614-F3949038-83E1-447B-9B48-AA836AB9B4FFQ59128232-13C8C474-6E21-47ED-A74F-0674CDB6CE7C
P2860
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@ast
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@en
type
label
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@ast
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@en
prefLabel
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@ast
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@en
P2093
P2860
P921
P356
P1476
Randomized Phase III Trial of ...... Breast Cancer: CALGB 40502/NC
@en
P2093
Alan P Lyss
Alvaro Moreno-Aspitia
Clifford Hudis
Constance Cirrincione
Deborah Toppmeyer
Edith A Perez
Eleanor Leung
Eric P Winer
Erica L Mayer
Hope S Rugo
P2860
P304
P356
10.1200/JCO.2014.59.5298
P407
P577
2015-06-08T00:00:00Z